Live Breaking News & Updates on Agonist Development Program

Stay updated with breaking news from Agonist development program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Liminal BioSciences Provides R&D Update

/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Company has nominated a lead. ....

United Kingdom , Bruce Pritchard , Liminal Biosciences Inc , Fairhaven Pharmaceuticals Inc , World Health Organisation , Agonist Development Program , Antagonist Development Program , Market Watch Research , Chief Executive Officer , Watch Research , Future Market Insights , Gary Bridger , Interim Chief Scientific Officer , Study Results , Liminal Biosciences Inc ,

Liminal BioSciences Inc.: Liminal BioSciences Provides R&D Update

LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseasesAdvancement of clinical trial application (CTA) ....

United Kingdom , Shrinal Inamdar , Bruce Pritchard , Kaitlin Gallagher , Exchange Commission , World Health Organisation , Market Watch Research , Securities Exchange , Fairhaven Pharmaceuticals Inc , Liminal Biosciences Inc , Agonist Development Program , Antagonist Development Program , Prnewswire Liminal Biosciences Inc , Chief Executive Officer , Watch Research , Future Market Insights , Gary Bridger , Interim Chief Scientific Officer , Study Results , About Liminal Biosciences , Securities Act , Securities Exchange Act , Liminal Bioscience , Nasdaq Listing Rule , Nasdaq Capital Market , Canadian Securities Administrators ,

Liminal BioSciences (LMNL) Provides R&D Update

Liminal BioSciences (LMNL) Provides R&D Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Bruce Pritchard , Liminal Biosciences Inc , Market Watch Research , Fairhaven Pharmaceuticals Inc , World Health Organisation , Agonist Development Program , Exchange Commission , Antagonist Development Program , Securities Exchange , Chief Executive Officer , Watch Research , Future Market Insights , Interim Chief Scientific Officer , Study Results , Securities Act , Securities Exchange Act , Liminal Bioscience , Nasdaq Listing Rule , Nasdaq Capital Market , Canadian Securities Administrators , Annual Report ,